-
GenScript ProBio, Eutilex Enter Cancer Collaboration
contractpharma
April 10, 2020
Partner on plasmid and virus process development and manufacturing for CAR-T programs.
-
China-based Biotech Laekna Acquires Global Rights to Develop and Commercialize anti-PD-L1 Antibody
oncozine
March 30, 2020
Laekna will receive exclusive global rights to FAZ053, an investigational anti-PD-L1 antibody being developed by Novartis for the treatment of patients with advanced forms of cancer.
-
Astellas, CytomX form T-cell engaging cancer antibodies partnership
pharmatimes
March 27, 2020
Astellas has entered into a new partnership with CytomX Therapeutics, in order to develop T-cell engaging bispecific antibodies targeting CD3 and tumour cell surface antigens for the treatment of cancer.
-
Mass cytometry could reveal best cancer drug regimens for clinical trials
europeanpharmaceuticalreview
March 25, 2020
Researchers have developed a new technology that could provide real-time analysis of patient samples during clinical trials to reveal the best cancer treatment regimens.
-
Lynparza Granted Orphan Drug Designation in Japan for Pancreatic Cancer
americanpharmaceuticalreview
March 23, 2020
AstraZeneca announced Lynparza (olaparib) has been granted orphan drug designation (ODD) in Japan for the maintenance treatment of germline BRCA-mutated (gBRCAm) curatively unresectable pancreatic cancer.
-
NICE fails to recommend pembrolizumab in final draft guidance
europeanpharmaceuticalreview
March 17, 2020
The UK NICE has not found pembrolizumab cost-effective for use on the NHS, after a review of evidence collected while the drug was available via the Cancer Drugs Fund.
-
EMA begins safety review of ifosfamide cancer medicines
europeanpharmaceuticalreview
March 17, 2020
The EMA has announced the results of its pharmacovigilance meeting for March, saying that it has started a review of medicines containing ifosfamide due to a higher risk of encephalopathy.
-
Statins starve cancer cells to death
worldpharmanews
March 16, 2020
More than 35 million Americans take statin drugs daily to lower their blood cholesterol levels. Now, in experiments with human cells in the laboratory ...
-
“Two-pronged” DNA repair attack could kill drug-resistant cancers
pharmatimes
March 16, 2020
A new study has suggested that launching a “two-pronged” attack on cancer’s ability to safeguard its DNA could offer an effective new way of treating the disease.
-
New genetic test could pick out ‘high risk’ bone marrow cancer patients
pharmatimes
March 13, 2020
Researchers have developed a new genetic test could help doctors pick out patients with the bone marrow cancer multiple myeloma who are at “ultra high risk” of their cancer progressing aggressively early on.